New York, NY -- (SBWIRE) -- 03/20/2017 -- Antibody Drug Conjugates Market: Drivers and Challenges
The global market for antibody drug conjugates is expected to be driven by the advancement in medical technology. The key drivers of the market are the increasing cases prevalence of cancer, growing ageing population and increase in obese population. Moreover, the increasing research activities on antibody therapies, preclinical research, more research on advanced drug discoveries and increasing research on oncology diseases and the growing collaboration between research institutes, Biotechnology and Biopharmaceuticals companies is also acting as a fuel to the market and is expected to drive the market of antibody drug conjugates within the forecast period of 2016-2024. However, the high cost of the procedures and the lack of fund can be the restraint for the growth of this market.
Antibody Drug Conjugates Market: Key Players
Some of the major players in global antibody drug conjugates market include Genentech USA, Inc., Seattle Genetics, F. Hoffmann-La Roche Ltd and Takeda Pharmaceuticals.
A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/13360
Antibody Drug Conjugates Market: Regional Overview
By regional presence, antibody drug conjugates market is segmented into five key regions viz. North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. North America will continue to dominate the antibody drug conjugates market as it has high experienced professionals and better healthcare facilities. Europe is expected to hold second largest market share in global antibody drug conjugates market. The growing government initiatives and increasing number of Biotechnology and Biopharmaceutical companies in APAC is also driving the market of antibody drug conjugates in APAC.
Request to View Tables of Content @ http://www.persistencemarketresearch.com/toc/13360